CLS Stock Recent News

Celestica reported Q4-CY24 revenue of $2.55B (+19% YoY), with CCS segment revenue surging 30% YoY to $1.74B. Full-year CY25 revenue is projected at $10.7B (+11% YoY), with adjusted EPS expected to hit $4.75 (+22% YoY). HPS within CCS grew 65% YoY, driven by AI-driven data center and networking demand.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Celestica is rated as a "Strong Buy" due to a 40% stock dip, presenting a golden buying opportunity for GARP investors. Despite tariff concerns, CLS's EPS growth, high operating margins, and strong demand from hyperscaler customers make the stock significantly undervalued by at least 31%. The company's transition to higher-value ODM services and robust CCS segment growth position it well for long-term stability and profitability.

- CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD - - Flexible Dosing and Extended Duration would be Important Differentiators from Existing Approved Therapies and Other Tyrosine Kinase Inhibitors in Development - ALPHARETTA, Ga., March 06, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the receipt of the formal meeting minutes from its recent End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) relating to CLS-AX (axitinib injectable suspension) for the treatment of neovascular age-related macular degeneration (wet AMD).

TAP, AVBH, CLS, FUNC and HBT have been added to the Zacks Rank #1 (Strong Buy) List on March 6, 2025.

AVBH, CLS and TAP made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 6, 2025.

Celestica (CLS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Celestica (CLS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, CLS broke through the 50-day moving average, which suggests a short-term bullish trend.

Pulling back from their 52-week highs, these top-rated stocks are viable options for long-term positions in the portfolio.

The average of price targets set by Wall Street analysts indicates a potential upside of 26.8% in Celestica (CLS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.